97 related articles for article (PubMed ID: 30048976)
1. Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells.
Jordheim LP; Chettab K; Cros-Perrial E; Matera EL; Dumontet C
Pharmacology; 2018; 102(3-4):161-168. PubMed ID: 30048976
[TBL] [Abstract][Full Text] [Related]
2. Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin.
van Huis-Tanja LH; Kweekel DM; Lu X; Franken K; Koopman M; Gelderblom H; Antonini NF; Punt CJ; Guchelaar HJ; van der Straaten T
Mutat Res; 2014 Jan; 759():37-44. PubMed ID: 24220697
[TBL] [Abstract][Full Text] [Related]
3. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
[TBL] [Abstract][Full Text] [Related]
4. Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.
Chen G; Qiu H; Ke SD; Hu SM; Yu SY; Zou SQ
World J Gastroenterol; 2013 Apr; 19(16):2481-91. PubMed ID: 23674849
[TBL] [Abstract][Full Text] [Related]
5. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
[TBL] [Abstract][Full Text] [Related]
6. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.
Graf N; Ang WH; Zhu G; Myint M; Lippard SJ
Chembiochem; 2011 May; 12(7):1115-23. PubMed ID: 21452186
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.
Ding X; Qu X; Fan Y; Che X; Qu J; Xu L; Liu J; Liu Y
Anticancer Drugs; 2014 Mar; 25(3):315-22. PubMed ID: 24300914
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
[TBL] [Abstract][Full Text] [Related]
9. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.
Youn CK; Kim MH; Cho HJ; Kim HB; Chang IY; Chung MH; You HJ
Cancer Res; 2004 Jul; 64(14):4849-57. PubMed ID: 15256455
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
[TBL] [Abstract][Full Text] [Related]
13. Biological and predictive role of ERCC1 polymorphisms in cancer.
Formica V; Doldo E; Antonetti FR; Nardecchia A; Ferroni P; Riondino S; Morelli C; Arkenau HT; Guadagni F; Orlandi A; Roselli M
Crit Rev Oncol Hematol; 2017 Mar; 111():133-143. PubMed ID: 28259288
[TBL] [Abstract][Full Text] [Related]
14. A review of excision repair cross-complementation group 1 in colorectal cancer.
Bohanes P; Labonte MJ; Lenz HJ
Clin Colorectal Cancer; 2011 Sep; 10(3):157-64. PubMed ID: 21855036
[TBL] [Abstract][Full Text] [Related]
15. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
[TBL] [Abstract][Full Text] [Related]
16. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
[TBL] [Abstract][Full Text] [Related]
17. Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.
Kap EJ; Popanda O; Chang-Claude J
Pharmacogenomics; 2016 May; 17(7):755-94. PubMed ID: 27183147
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
19. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
20. The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
Sreekumar R; Al-Saihati H; Emaduddin M; Moutasim K; Mellone M; Patel A; Kilic S; Cetin M; Erdemir S; Navio MS; Lopez MA; Curtis N; Yagci T; Primrose JN; Price BD; Berx G; Thomas GJ; Tulchinsky E; Mirnezami A; Sayan AE
Mol Oncol; 2021 Aug; 15(8):2065-2083. PubMed ID: 33931939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
